Drug Discovery Alliances

What Drug Discovery Alliances does

Drug Discovery Alliances (DDA) is a privately held pharmaceutical R&D intermediary founded in 2001 by Deborah Minor, Ph.D., and headquartered in North Carolina. The firm operates a platform that connects emerging biotech, mid-market pharmaceutical, generic drug, and nutraceutical companies with a curated network of CMC consultants, contract research organizations (CROs), contract development and manufacturing organizations (CDMOs), and API/excipient suppliers. DDA is compensated through professional services fees for CMC consulting and project management, transactional brokerage fees on introductions to manufacturing partners, and managed services arrangements spanning the lifecycle from preclinical development through commercialization.

DDA's service catalog spans the full pharmaceutical development continuum. On the discovery side it offers preclinical development, process research, solid form and crystallization capabilities, analytical method development, high-throughput catalytic screening, and antibody manufacturing. On the development side it brokers API manufacturing, regulatory starting materials and advanced intermediates, formulation development (including OEB4/OEB5 highly potent compounds), generic API manufacturing, peptides and oligonucleotide/carbohydrate API sourcing, and quality and regulatory support covering GMP auditing, FDA NDA/ANDA submissions, and clinical supplies management. The platform is delivered through a bench of more than ten vetted CMC consultants with credentials spanning ex-Merck, ex-J-STAR Research, Rhone Poulenc, Accelrys, and MDL, rather than through proprietary software.

DDA monetizes primarily via professional services engagements tied to CMC consulting hours and project management, supplemented by transaction-fee style introductions to manufacturing partners within its preferred supplier network. Its go-to-market combines direct outreach by CMC consultants, content marketing via its blog and a gated corporate PDF, LinkedIn presence, Calendly-scheduled free consultations, and participation in industry events such as ChemOutsourcing and CPHI. Certified as a WBENC woman-owned business, an SBA HubZone contractor, and an SAP Ariba Network Partner, DDA also pursues federal contracting and corporate supplier-diversity channels as secondary routes to market.

Name

Drug Discovery Alliances

Legal name

Drug Discovery Alliances

Website

https://drugdiscoveryalliances.com

Company type

Private

Founded year

2001

Operating status

Operating

Headcount range

1–10 employees

Short description

Drug Discovery Alliances (DDA) is a North Carolina-based pharmaceutical R&D intermediary connecting biotech and pharmaceutical companies with CMC consultants and a global network of CROs, CDMOs, and API manufacturers to advance programs from discovery through commercialization.

Ownership category

akta.pro rank

Product category

Pharmaceutical R&D Consulting Services

NAICS

Research and Development in the Physical, Engineering, and Life Sciences (54171), Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Management Consulting Services (8742)

akta.pro primary industry

CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD)

akta.pro secondary industries

Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM), Drug Substance–Drug Product Integrated CDMO (HLAGABAG), Companion Diagnostics (CDx) & Therapy Selection Assays (HLAAALAF)

Keywords

• CMC consulting services
• Pharmaceutical R&D
• Drug development consulting
• API manufacturing sourcing
• Pharmaceutical networking platform

Headquarters

HQ city

Raleigh

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

1. CMC Consulting Services: DDA connects clients with a vetted network of over ten CMC consultants providing expertise across biologics, small molecules, and complex pharmaceutical development programs. Consultants cover process development, analytical R&D, regulatory strategy, technology transfer, GMP compliance, and scale-up manufacturing.
2. Pharmaceutical R&D Platform Services: The company acts as a broker/platform connecting pharmaceutical companies with manufacturers and preferred suppliers. Services span from discovery phase to commercialization, customized to client needs at each phase.
3. API Manufacturing Brokerage: DDA matches pharmaceutical companies with API manufacturers based on specific requirements such as process research, chemistry, volume, and development phase through their established network of trusted partners.
4. Preclinical Development Services: Integrated preclinical development services including lead optimization, toxicology, pharmacokinetics, regulatory compliance, and IND application preparation support.

Pricing tiers

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

Core offering

Drug Discovery Alliances is a pharmaceutical R&D platform that connects pharmaceutical and biotech companies with a vetted network of more than ten CMC consultants and a global network of preferred CRO, CDMO, and manufacturing partners. The company delivers end-to-end services from discovery through commercialization, providing CMC consulting and project management, API manufacturing matchmaking, formulation development, regulatory and quality support, and specialized discovery capabilities (solid form screening, crystallization, catalytic screening, antibody manufacturing) under FDA and EMA compliance frameworks.

Product overview

Drug Discovery Alliances operates as a pharmaceutical R&D platform backed by an integrated team of CMC consultants and a global network of preferred suppliers. The company provides end-to-end services spanning drug discovery (preclinical development, process research, solid form capabilities, crystallization, analytical method development, catalytic screening, and antibody manufacturing) and drug development (API manufacturing, RSMs and advanced intermediates, formulation development, generic manufacturing, quality and regulatory support, and peptides/oligonucleotides/carbohydrate manufacturing). Services are delivered through project management, consulting engagements, and facilitated connections to CROs and CDMOs across the development continuum from discovery to commercialization.

Differentiator

Problem solved

Functional benefit

Products and services

• CMC Project Management Chemistry, Manufacturing, and Controls (CMC) consulting and project management services that guide pharmaceutical companies through regulatory requirements including process chemistry, medicinal chemistry, analytical CMC, and regulatory strategy.
• API Manufacturing Active Pharmaceutical Ingredient manufacturing through a network of trusted partners, covering small molecules, oligonucleotides, carbohydrates, antibiotics, and fermentation-based products from preclinical through commercial scale.
• RSMs and Advanced Intermediates Regulatory Starting Materials (RSMs) and advanced intermediate manufacturing solutions including process research, optimization, pilot production, and large-scale production under FDA compliance.
• Formulation Development Drug product development services from initial formulation through clinical trials and specialized manufacturing, including solid dosage forms, sterile forms, and handling of highly potent compounds (OEB4/OEB5).
• Generic Manufacturing Generic Active Pharmaceutical Ingredient manufacturing under strict cGMP conditions with rigorous quality systems and international compliance standards.
• Quality and Regulatory Support Regulatory compliance and quality assurance services including clinical supplies management, auditing, training, FDA submission support (NDA/ANDA), and due diligence services.
• Peptides, Oligonucleotides, Carbohydrate Manufacturing Bio-organic API manufacturing for peptides, oligonucleotides, lipids, and carbohydrates using solid-phase, solution-phase, and hybrid technologies with GMP facilities across Europe and the USA.
• Preclinical Development Services Preclinical development bridging discovery to clinical trials, including lead refinement, pharmacokinetics (DMPK), toxicology assessments, IND application preparation, and regulatory support.
• Process Research API synthesis process optimization ensuring reliability and compliance from preclinical through clinical phases, with focus on cost-effectiveness and regulatory standards.
• Solid Form Capabilities Salt and polymorph screening services including crystal discovery, salt/cocrystal screens, polymorph advantage identification, thermodynamic stability assessment, and process robustness evaluation.
• Crystallization API crystallization control and optimization across preclinical, clinical, and commercialization phases ensuring FDA-compliant polymorph consistency in clinical trial materials.
• Analytical Method Development Analytical method development and testing services connecting clients with CROs and laboratories for HPLC/GC methods, LC/MS, NMR, reference standard certification, impurity identification, and stability studies.
• Catalytic Screening Catalytic reaction development using high throughput 96-well screening, catalyst optimization, process optimization via DoE, kinetic analysis, scale-up, and technology transfer.
• Antibody Manufacturing End-to-end antibody R&D and manufacturing including custom monoclonal/polyclonal development, GMP-compliant scale-up, and quality compliance (GMP, GLP, ISO certifications).
• CMC Consulting Access to a network of over ten CMC consultants with expertise across biologics, small molecules, and complex pharmaceutical programs covering process development, analytical R&D, regulatory strategy, technology transfer, GMP compliance, and scale-up.

Quantifiable outcome

• 25 years of industry experience driving programs from discovery to commercialization
• +2 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Nine partnerships are on record, tiered core.

• SBA HubZone ProgramcoreOthersHubZone certification through the U.S. Small Business Administration provides priority access to federal contract opportunities and supports diversity and inclusion goals.
• Women's Business Enterprise National Council (WBENC)coreOthersWBENC certification confirms DDA as a woman-owned business, supporting supplier diversity goals and providing access to corporate diversity initiatives.
• Antibody Manufacturing PartnerscoreStrategic or Co-development PartnerPartners with facilities offering GMP, GLP, and ISO certifications for antibody R&D and manufacturing, providing end-to-end support from early-stage discovery through large-scale production.
• API Manufacturing NetworkcoreStrategic or Co-development PartnerEstablished network of API manufacturing partners with proven FDA regulatory track records, offering capabilities across small molecules, oligonucleotides, carbohydrates, antibiotics, and fermentation products from preclinical through commercial scale.
• Regulatory Firm PartnershipcoreImplementation/ SI/ Consulting PartnerDDA partnered with a regulatory firm to ensure supplier regulatory compliance and FDA approval readiness, covering clinical supplies project management, quality assurance, auditing, training, and regulatory submissions.
• Peptide and Oligonucleotide Manufacturing PartnerscoreStrategic or Co-development PartnerPartners with three cGMP peptide API facilities offering solid-phase, solution-phase, and hybrid manufacturing, along with extensive downstream processing and preparative HPLC purification for oligonucleotide manufacturing.
• Formulation Development PartnerscoreStrategic or Co-development PartnerPartnership with industry leaders for comprehensive drug product development covering solid dosage forms, sterile forms, highly potent compounds (OEB4/OEB5), and clinical trial preparations including comparator sourcing and packaging.
• Process Research PartnerscoreStrategic or Co-development PartnerAccess to world-leading process research capabilities for API synthesis optimization, ensuring process reliability, compliance, and consistency from pre-clinical through clinical stages.
• Andy Thompson (Chemistry Consultant)coreOthersAndy Thompson serves as chemistry consultant, bringing over four decades of organic chemistry experience including process chemistry at Merck and founding/leading J-STAR Research until 2023.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Lonza: Global CDMO with API, biologics, and formulation capabilities at commercial scale; relevant as a comparable destination manufacturer within DDA's preferred-supplier network.
• Cambrex: Small-molecule API CDMO offering process development, scale-up, and GMP manufacturing across the full lifecycle—represents one of the supply-side categories DDA brokers client introductions into.
• Eurofins Discovery: Large-scale provider of discovery, analytical, and CMC services spanning medicinal chemistry, formulation, and contract testing—a broad incumbent offering the same outsourced workflow capabilities DDA routes through its network.
• Catalent: Global CDMO providing API and drug product development services including formulation and fill-finish; a leading destination that DDA channels biopharma clients toward.

Direct peers

• Scientist.com: Operates a marketplace that connects pharmaceutical and biotech researchers with contract research service providers across preclinical and CMC services—a comparable brokerage/intermediary model to DDA's supplier-matching platform.
• J-STAR Research: Specialty contract chemistry CRO founded by Andy Thompson and historically led by Mark Cameron, both now consultants to DDA. Direct overlap on process chemistry, route scouting, and CRO service delivery supporting DDA's network partner roster.
• ProPharma Group (formerly PharmaLex): Provides regulatory affairs and CMC consulting services to pharma and biotech, addressing FDA/EMA submissions, quality, and technical writing—an adjacent CMC consulting peer to DDA's project management and regulatory offering.

Emerging players

• LabConnect: Aggregator/network model providing scientific services and central lab solutions to biopharma, comparable to DDA's role in curating and coordinating a multi-vendor network for emerging biotech clients.
• Bionova Scientific: CDMO with biologics and antibody manufacturing capabilities aligned to DDA's antibody R&D and manufacturing offering, providing a comparable specialized destination for DDA's biotech clients.
• ChemPartner: Integrated CRO/CDMO providing discovery chemistry, CMC, and API manufacturing services—a comparable integrated peer for DDA's discovery-to-commercialization positioning.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/drug-discovery-alliances

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Drug Discovery Alliances